Sun Yuliang, Cheng Weishi, Shen Jing, Zhen Hongnan, Guan Hui, He Lei, Hu Ke, Zhang Fuquan, Liu Zhikai
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251356924. doi: 10.1177/15330338251356924. Epub 2025 Jul 6.
IntroductionThis study aims to evaluate diagnosis, treatment and clinical outcomes for patients with cervical cancer in pregnancy (CCIP) and their fetuses over a 10-year period, providing clinical evidence for the management of CCIP.MethodsClinical data of 28 patients diagnosed with CCIP at our center between January 1st, 2013 and June 30th, 2023 were retrospectively analyzed, focusing on gestational age at diagnosis, treatment, and maternal-fetal outcomes.ResultsA total of 28 patients with CCIP were identified, accounting for 0.42% (28/6678) of patients with cervical cancer during the study period. The majority of patients (86%, 24/28) had squamous cell carcinoma diagnosed by colposcopic biopsy, and 21 patients presented with recurrent vaginal bleeding. Cervical cancer was diagnosed during pregnancy in 19 cases and in the postpartum period in 9 cases. The mean tumor diameter was 5.4 (2-12) cm. Among 19 patients diagnosed during pregnancy, 13 patients chose pregnancy preservation, resulting in an average delay of treatment by 16.4 (0-33) weeks without observed disease progression. Fetuses were delivered via cesarean section at an average gestational age of 36.3 weeks; eight of these patients received neoadjuvant chemotherapy. At a median follow-up duration of 40.1 (12-103) months, 25 patients survived. Disease-free survival was observed in 20 patients, whereas two patients experienced local progression, and six developed distant metastases.ConclusionClinical outcomes for patients with CCIP appear comparable to those observed in non-pregnant patients in the general population. Pregnant patients presenting with abnormal vaginal bleeding should undergo prompt cervical cancer screening to enable early diagnosis and tailored management strategies. For patients with a strong desire to maintain their pregnancy, careful consideration should be given to postponing delivery until fetal maturity, thereby minimizing maternal and fetal complications and improving maternal and fetal outcomes.
引言
本研究旨在评估妊娠合并宫颈癌(CCIP)患者及其胎儿在10年期间的诊断、治疗及临床结局,为CCIP的管理提供临床依据。
方法
回顾性分析2013年1月1日至2023年6月30日期间在本中心确诊为CCIP的28例患者的临床资料,重点关注诊断时的孕周、治疗情况及母胎结局。
结果
共确定28例CCIP患者,占研究期间宫颈癌患者的0.42%(28/6678)。大多数患者(86%,24/28)经阴道镜活检诊断为鳞状细胞癌,21例患者出现反复阴道出血。19例在孕期诊断为宫颈癌,9例在产后诊断。肿瘤平均直径为5.4(2 - 12)cm。在孕期诊断的19例患者中,13例选择保留妊娠,平均推迟治疗16.4(0 - 33)周,未观察到疾病进展。胎儿平均在孕36.3周时通过剖宫产分娩;其中8例患者接受了新辅助化疗。中位随访时间为40.1(12 - 103)个月,25例患者存活。20例患者无病生存,2例出现局部进展,6例发生远处转移。
结论
CCIP患者的临床结局似乎与普通人群中非妊娠患者的临床结局相当。出现异常阴道出血的孕妇应及时进行宫颈癌筛查,以便早期诊断并制定针对性的管理策略。对于强烈希望维持妊娠的患者,应谨慎考虑推迟分娩至胎儿成熟,从而尽量减少母胎并发症并改善母胎结局。